Rallybio Corporation (RLYB) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Rallybio Corporation (RLYB:NASDAQ), powered by AI.

Current Price
$14.12
P/E Ratio
-1.3
Market Cap
77M
Sector
Healthcare
What is the Rallybio Corporation stock price forecast?

Rallybio Corporation is currently trading at $14.12. View real-time AI analysis on Alpha Lenz.

What is Rallybio Corporation insider trading activity?

View the latest insider trading data for Rallybio Corporation on Alpha Lenz.

What is Rallybio Corporation's P/E ratio?

Rallybio Corporation's P/E ratio is -1.3.

Rallybio Corporation

NASDAQ · RLYB
$14.12
Ask about Rallybio Corporation's future dividend policy...
Alpha Chat Insight

Rallybio Corporation trades at a P/E of -1.3 (undervalued) with modest ROE of -68.8%.

Ask for details

Company Overview

Rallybio Corporation is a biopharmaceutical company focusing on the development and commercialization of transformative therapies for severe and rare diseases. The company's primary purpose is to harness scientific advancements to address unmet medical needs, targeting life-threatening conditions that often lack effective treatment options. Rallybio invests in research and partnerships to explore innovative therapeutic approaches, with an emphasis on speed and efficiency in drug development. The sectors most impacted by Rallybio's work include biotechnology and healthcare, particularly concerning genetic disorders and immunological diseases. As a player within the biopharmaceutical space, the company contributes to the broader healthcare industry's efforts to improve patient outcomes and advance medical science. Rallybio's strategic collaborations with global research institutions and its commitment to scientific excellence underscore its significant role in delivering medical breakthroughs to the market. Launched with a mission to make a difference in patients’ lives, Rallybio embodies the forward momentum of biopharmaceutical innovation.

CEODr. Stephen Uden M.B, M.D.
SectorHealthcare
IndustryBiotechnology
Employees20

Company Statistics

FY 2024

Profile

$76.86MMarket Cap
$636.00KRevenue
0.00Shares Out
20Employees

Margins

N/AGross
-9491.35%EBITDA
-9511.95%Operating
-9084.12%Pre-Tax
-9084.12%Net

Valuation

-1.33P/E
1.25P/B
120.84EV/Sales
-1.05EV/EBITDA
-1.56P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-62.89%ROA
-68.85%ROE
-65.85%ROIC

Financial Health

$13.90MCash & Cash Equivalents
$-7.45MNet Debt
10.47%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Rallybio Corporation (ticker: RLYB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 20 employees. Market cap is $77M.

The current price is $14.12 with a P/E ratio of -1.33x and P/B of 1.25x.

ROE is -68.85% and operating margin is -9511.95%. Annual revenue is $636,000.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Rallybio Corporation (Healthcare) Stock Forecast & Analysis $14.12 | Alpha Lenz